1.5 Billion Heartbeats
The Biological Scaling Laws of Money and Why Corporations Die
This series was inspired by conversations with my daughter, who is studying A-Level physics, and the questions she brought home about what time actually is.
A mouse lives roughly 18 months. An elephant lives for 70 years. The mouse’s heart races at 600 beats per minute; the elephant’s thumps at a steady 30. Yet both animals will experience approximately 1.5 billion heartbeats before they die.
The mouse just burns through the budget faster.
This single fact — uncovered by physicist Geoffrey West while studying the mathematics of living systems — contains one of the most powerful investing insights of the last century. Every company you own has a heartbeat. Most investors have no idea how fast it’s racing, or how many beats are left.
The Metabolism of a Corporation
West’s research, detailed in his book Scale, revealed a mathematical pattern governing nearly all living things: as organisms grow larger, their metabolic rate doesn’t grow proportionally. A creature ten times larger doesn’t need ten times the energy — it needs only about seven and a half times as much. Bigger organisms run more efficiently, but they also run more slowly. Scientists call this sub-linear scaling.
The principle maps onto companies with startling precision.
A startup is a shrew. It operates at fever pitch — burning cash, iterating rapidly, taking risks that would be catastrophic for a larger organism. It is inefficient in the way all young, energetic things are inefficient: it burns more energy per unit of output, but it generates ideas and adaptations at extraordinary speed.
As that startup grows, the advantages of scale accumulate. Procurement costs fall. Brand recognition compounds. Financing becomes cheaper. But something else happens simultaneously. The company begins to slow. Decisions require more approval layers. Meetings multiply. The compliance department doubles in size. Innovation — once the entire point of the enterprise — starts competing with bureaucratic maintenance for the same limited pool of energy.
The company has entered its elephant phase. It is larger, more efficient, and fundamentally slower.
Most investors never see the transition. They buy into a fast-growing company and project that growth rate forward indefinitely, as if the shrew could live forever at shrew speed. It cannot. The laws of biological scaling apply to corporations just as reliably as they apply to mammals.
Why Corporations Die
West’s research goes further than explaining why companies slow down. It explains why they die.
Every living system depends on a distribution network. In animals, it’s the vascular system — blood vessels that must carry nutrients to every single cell. In corporations, it’s the organizational network — communication chains, supply chains, reporting structures — that must connect every employee, every product, and every customer.
As these networks expand to fill space, something mathematically inevitable happens: the cost of maintaining the network begins to outpace the value it delivers. In a company, this looks like layers of management whose primary job is managing other managers. It looks like legal and compliance costs growing faster than revenue. It looks like information taking three weeks and four committee meetings to travel from the front line to a decision-maker.
Eventually, the metabolic cost of simply staying alive consumes every available calorie. The company reaches stasis. Any external shock — a nimble competitor, a technological shift, a regulatory change — becomes potentially fatal, because there is no surplus left to absorb it.
They didn’t fail. They simply burned through their 1.5 billion heartbeats, and the network that once sustained them became the network that strangled them.
This is why the average lifespan of an S&P 500 company has collapsed from 60 years in the 1950s to fewer than 20 years today. These are not failed companies. Many were dominant in their era. They built the defining products and infrastructure of their generation.
The Exception That Changes Everything
Here is where West’s research takes a turn that should reshape how you think about building a portfolio.
While organisms scale sub-linearly — getting bigger, growing slower — cities scale super-linearly. When a city doubles in population, its economic outputs (wages, patents, new businesses, creative collisions) grow by a factor of roughly 1.15 per capita. Double the people, and you get more than double the innovation. The returns accelerate with size rather than decelerating.
Cities don’t die. You can bomb them, flood them, and destroy their infrastructure. Carthage, Hiroshima, Detroit — cities survive shocks that would permanently end any company. Why? Because a city isn’t an organism. It’s a network of networks. Its value comes not from any individual person or business, but from the density and diversity of connections between them. Every new person who joins increases the number of possible connections exponentially. The collisions between different ideas, industries, and cultures generate returns that compound indefinitely.
The investment implication is direct: organisms die; networks don’t.
Organisms vs. Networks: The Only Distinction That Matters
An individual smartphone manufacturer is an organism. It makes things, sells things, and is subject to the full weight of sub-linear scaling — growing slower and more fragile as it gets larger. The app store that connects millions of developers to billions of users is a network. Its value grows faster than its size, and it doesn’t die when any single participant leaves.
A specific clothing brand is an organism. The e-commerce platform on which ten thousand clothing brands compete is a network. A single coffee exporter is an organism. The regional logistics hub connecting East African producers to global markets is a network.
If you want a portfolio built to last decades rather than years, you need to identify which of your holdings are organisms and which are networks — and weight your capital accordingly. Networks deserve a premium that most valuation models do not capture, precisely because they don’t follow the biological death curve.
Arbitraging the Death Curve
Understanding biological scaling reveals a specific and repeatable investment strategy.
There is a predictable moment in every large company’s life when fast capital abandons it. Revenue growth slows. The stock price craters. Analysts downgrade it from “growth” to “value.” The narrative shifts from excitement to disappointment. For an investor whose internal clock is running fast, this moment is a reason to sell.
For patient capital, it is an opportunity.
A company that has successfully built its distribution network over decades — even if it can no longer expand that network significantly — has already done the hardest work. It doesn’t need to grow to be valuable. It can simply distribute the surplus it generates: dividends, share buybacks, and steady free cash flow, year after year, long after the growth investors have moved on.
You are not buying the growth story. You are buying the residual heartbeats. And a well-maintained elephant, even in its later years, can produce extraordinary returns for an investor willing to hold it through the slow, steady rhythm of its remaining beats.
The arbitrage works because markets are structurally biased toward growth narratives. Fast capital, by its nature, cannot wait. When growth slows, it must leave. Patient capital steps in, acquires the yield at a discount, and collects for years.
Three Questions to Apply the Biological Lens
Where is this company on the scaling curve?
Is it still in shrew phase — burning fast, iterating constantly, taking losses to capture market share? Or has it entered elephant phase — efficient, stable, but structurally unable to grow at historical rates? Buying a shrew at elephant prices is one of the most common and most painful mistakes in investing.
Is this an organism or a network?
Does the company’s value come from what it produces directly, or from the connections it facilitates between other producers and consumers? Networks tend to survive. Organisms tend to peak, plateau, and decline. The distinction is worth more than any price-to-earnings ratio.
How much metabolic surplus does it carry?
A company with strong free cash flow and manageable debt has surplus energy to absorb shocks, fund adaptation, and return capital to shareholders. A company burning cash at scale while growth stalls is approaching stasis — impressive to look at, but structurally fragile when the next external shock arrives.
The Bigger Picture: Buy the Network Formation
In frontier and emerging markets, this framework becomes particularly powerful. These are economies in transition — moving from collections of individual organisms (small businesses, informal traders, disconnected producers) to interconnected networks (digital payment infrastructure, regional logistics platforms, mobile-first financial systems).
That transition from sub-linear to super-linear scaling is exactly where the most extraordinary returns in investment history have always appeared. It happened in the United States in the early twentieth century. In South Korea in the 1970s. In China in the 1990s. In each case, the investor who understood they were buying into the formation of a network — not just a collection of individual companies — captured returns that dwarfed everything else available.
The challenge is patience. Networks take time to form. The connections that generate super-linear returns don’t appear overnight. But when they do, they compound in ways no individual organism can match.
Stop looking for the next big company.
Start looking for the next big network.
Professional overthinker. Occasional optimist. Building a platform for #InvestinAfrica - driving impact through capital, innovation, and technology.
See the rest of the articles in the series here:
Article 1, The Unified Theory of Investing: The Illusion of the Clock